{"contentid": 488262, "importid": NaN, "name": "UK patients to benefit from five-minute breast cancer treatment", "introduction": "Breast cancer patients undergoing chemotherapy will be offered a new combined treatment, Phesgo, which is injected and takes as little as five minutes to prepare and administer, compared with two infusions that can take up to two and a half hours, NHS England has announced.", "content": "<p>Breast cancer patients undergoing chemotherapy will be offered a new combined treatment, Phesgo, which is injected and takes as little as five minutes to prepare and administer, compared with two infusions that can take up to two and a half hours, NHS England has announced.</p>\n<p>Swiss pharma giant Roche&rsquo;s (ROG: SIX) Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, was approved by the European Commission in December last year, at which time the European regulatory decision still applied to the UK under the Brexit transition arrangements.</p>\n<p>More than 3,600 new patients each year will benefit from the treatment, as well as others who will switch from the treatment they are on to the single injection, following an NHS deal with the manufacturer. Pricing details were not disclosed.</p>\n<p>The injection will be offered to eligible people with HER2-positive breast cancer, which accounts for 15% of all breast cancers, and can be given alongside chemotherapy or on its own.</p>\n<h2><strong>Roche and NHS decision-makers working together</strong></h2>\n<p>&ldquo;Approval of Phesgo being used on the NHS in England is fantastic news as thousands of women with HER2 positive breast cancer will now benefit from a quicker and kinder treatment method,&rdquo; said Baroness Delyth Morgan, chief executive of Breast Cancer Now, adding: &ldquo;Today&rsquo;s announcement reflects the latest of continued advances in breast cancer treatment, and now we hope to see Roche and NHS decision-makers working together to ensure Phesgo is rapidly made available across all of the UK so that even more patients and healthcare professionals alike can reap its benefits.&rdquo;</p>\n<p>&ldquo;The COVID-19 pandemic has underlined the need to use novel approaches that help to minimise pressure on our healthcare system. We are delighted that people in England will continue to benefit from the latest advancements in cancer care, and this news shows how we are advancing science to achieve this,&rdquo; commented Richard Eaton, breast cancer lead at Roche Products, UK.</p>", "date": "2021-04-06 13:44:00", "meta_title": "UK patients to benefit from five-minute breast cancer treatment", "meta_keywords": "Roche, Phesgo, Pertuzumab, Trastuzumab, Cancer, Breast, NHS England, Deal", "meta_description": "UK patients to benefit from five-minute breast cancer treatment", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-06 13:43:46", "updated": "2021-04-06 13:53:10", "access": NaN, "url": "https://www.thepharmaletter.com/article/uk-patients-to-benefit-from-five-minute-breast-cancer-treatment", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "nhs_big.jpg", "image2id": "nhs_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Breast cancer, NHS", "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "Switzerland, UK", "company_tag": "Roche", "drug_tag": "pertuzumab, Phesgo, trastuzumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-06 13:44:00"}